Politics and Covid fail to dent UK fee pool optimism

David Rothnie

January 14, 2021 05:15 pm

AstraZeneca_PA_575x375_14January2021 — A medical syringe and vials are seen in front of AstraZeneca logo in this creative photo illustration. The European Medicines Agency (EMA) received an application for conditional marketing authorization of the COVID-19 vaccine developed by AstraZeneca and Oxford University, as media reported on 12 January 2021. (Photo by STR/NurPhoto) | STR/NurPhoto/PA Images

Bankers are betting on a strong year for the UK — Europe’s biggest fee pool — but the overlapping concerns of Brexit, Covid-19 and regulation make for an uncertain outlook, writes David Rothnie.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login

✔ 4,000 annual insights
✔ 700+ notes and long-form analyses
✔ 4 capital markets databases
✔ Daily newsletters across markets and asset classes
✔ 2 weekly podcasts

Topics

Equity EMEA Corporate Bonds Southpaw News content Loans and High Yield LevFin High Yield Bonds Leveraged LoansSynd Loans People and MarketsComment LevFin Leveraged Loans LevFin People and Markets Europe Corp People and Markets Investment Grade Loans Equity People and Markets Syndicated Loans Citi People and Markets Bank Strategy Top Stories High yield LevFin High grade and crossover bonds

DR

David Rothnie